Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b sham-controlled dose-ranging trial of intravitreal JNJ-81201887 for geographic atrophy secondary to AMD
MOH_2023-07-12_012423Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-81201887 in geographic atrophy (GA) and age-related macular degeneration (AMD) (3 arms), sponsored by Janssen Pharmaceutical. Started Jan 2023; status: completed.
02
Drugs
JNJ-81201887
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on MOH_2023-07-12_012423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-12_012423.